Sponsor or institution

Clinical trials and research at Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

• 14Clinical trials
• 6Countries

Newest trials

All recruiting trials (14)

• Tislelizumab treatment for people with lung cancer in routine care

  We will see how tislelizumab is used and how patients with resectable, locally advanced, or extensive-stage lung cancer do when treated in everyday clinical care in Germany and Austria.

  Recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Sankt Pölten, Lower Austria and 1 other locations · NCT07510724

• Neoadjuvant Cemiplimab for Merkel Cell Carcinoma in Stage I–II

  This study tests whether giving Cemiplimab before surgery helps people with early-stage Merkel cell carcinoma see if tumors shrink or disappear before sentinel node biopsy.

  Recruiting at 11 sites Phase 2 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Heidelberg, Baden-Wurttemberg and 11 other locations · NCT07387198

• TIPS benefits for people with hepatocellular carcinoma taking Tecentriq (atezolizumab) plus Avastin (bevacizumab) as first-line therapy.

  This study will try to see if placing a TIPS device helps people with advanced or unresectable hepatocellular carcinoma who are starting first-line treatment with Tecentriq plus Avastin.

  Recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Düsseldorf, North Rhine-Westphalia · NCT07365930

• Ivosidenib as maintenance after adjuvant chemotherapy for curative IDH1‑mutant intrahepatic cholangiocarcinoma

  This trial tests whether taking ivosidenib after standard adjuvant chemotherapy can reduce recurrence in adults with completely removed (R0) IDH1‑mutant intrahepatic cholangiocarcinoma.

  Recruiting at 15 sites Phase 2 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Aachen and 14 other locations · NCT07260175

• Zanidatamab with pembrolizumab and chemotherapy for HER2- and PD-L1-positive metastatic gastroesophageal adenocarcinoma

  This trial tests whether adding zanidatamab to pembrolizumab plus chemotherapy helps people with untreated HER2- and PD-L1-positive metastatic gastroesophageal adenocarcinoma.

  Recruiting at 14 sites Phase 2 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Berlin and 19 other locations · NCT07176312

• Enfortumab vedotin plus avelumab as first-line treatment for advanced penile cancer

  This trial tests whether combining enfortumab vedotin with avelumab helps men with advanced or metastatic penile squamous cell carcinoma as first-line treatment.

  Recruiting at 9 sites Phase 2 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Dresden and 8 other locations · NCT07110038

• Tislelizumab plus FLOT given before surgery for operable esophagus or stomach adenocarcinoma

  This trial tests whether adding the immunotherapy drug tislelizumab to FLOT chemotherapy given before surgery helps people with locally advanced, resectable esophagus or stomach adenocarcinoma shrink tumors and better tolerate treatment.

  Recruiting at 2 sites Phase 1 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Frankfurt and 3 other locations · NCT07059299

• Cemiplimab as first-line treatment for advanced basal cell carcinoma

  This trial will try cemiplimab as a first-line treatment for adults with locally advanced basal cell carcinoma who have not received hedgehog inhibitors.

  Recruiting at 8 sites Phase 2 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Erfurt and 7 other locations · NCT06981325

• Fruquintinib plus tislelizumab versus trifluridine/tipiracil plus bevacizumab for MSS/pMMR metastatic colorectal cancer without active liver metastases

  This trial tests whether combining fruquintinib with tislelizumab works better than trifluridine/tipiracil plus bevacizumab for adults with MSS/pMMR metastatic colorectal cancer who do not have active liver metastases.

  Recruiting at 15 sites Phase 2 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Linz and 22 other locations · NCT06856837

• Futibatinib plus chemo-immunotherapy for colorectal and other solid tumors

  This study tests whether adding the oral drug futibatinib to standard chemotherapy and the immunotherapy tislelizumab helps people with unresectable or metastatic colorectal cancer when given as first-line treatment.

  Recruiting at 6 sites Phase 2 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Amberg and 9 other locations · NCT06722183

• Combining Durvalumab with Radiofrequency Ablation for Treating Extrahepatic Cholangiocarcinoma

  This study is testing if combining a new immunotherapy with radiofrequency ablation and chemotherapy can help people with a type of bile duct cancer that can't be surgically removed.

  Recruiting at 12 sites Phase 2 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Aachen and 11 other locations · NCT06440993

• Stopping CDK4/6 inhibitors for patients with advanced breast cancer

  This study is testing whether stopping CDK4/6 inhibitors helps people with advanced breast cancer who have been stable on treatment for a while, while they continue other hormone therapies.

  Recruiting at 10 sites Phase 2 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Berlin and 12 other locations · NCT06207734

• Comparing atezolizumab plus bevacizumab to TACE for liver cancer treatment

  This study is testing if a combination of two drugs, atezolizumab and bevacizumab, works better than a standard treatment called TACE for people with intermediate-stage liver cancer.

  Recruiting at 72 sites Phase 3 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Graz and 71 other locations · NCT04803994

• Registry for patients with sarcoma and carcinosarcoma in Germany

  This study is gathering information from patients with sarcoma and carcinosarcoma in Germany to better understand their treatments and improve care for these rare tumors.

  Recruiting at 21 sites Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Tübingen, Baden-Wurttemberg and 20 other locations · NCT04122872

Quick answers

How many clinical trials run by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest are recruiting right now?

14, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 6 countries. The most sites are in Germany (14 trials), Austria (3 trials), France (1 trial), Italy (1 trial), Japan (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 9, Phase 1: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →